









市场行情
/
股票
/
nasdaq-krro
/

Korro Bio Inc

KRRO

8.120USD

-0.290-3.45%

收盘 12/26, 16:00（美东）报价延迟15分钟

76.31M总市值

亏损市盈率 TTM



Korro Bio Inc

8.120

-0.290-3.45%

概览公司财务分析

概览

公司

财务

分析

关于 Korro Bio Inc 公司

Korro Bio, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops, and commercializes genetic medicines based on editing ribonucleic acid (RNA), enabling treatment of both rare and highly prevalent diseases. The Company is generating a portfolio of differentiated programs that are designed to harness the body’s natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, it is expanding the reach of genetic medicines. Using its oligonucleotide-based approach, the Company brings its medicines to patients by leveraging its proprietary platform. The Company’s first development candidate, KRRO-110, is in development as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD) that has the potential to be disease-modifying and provide a differentiated therapeutic option.

Korro Bio Inc简介



公司代码KRRO

公司名称Korro Bio Inc

上市日期Oct 03, 2019

CEODr. Ram Aiyar, Ph.D.

员工数量104

证券类型Ordinary Share

年结日Oct 03

公司地址One Kendall Square. Building 600-700

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编02139

电话16174681999

网址https://www.korrobio.com/

公司代码KRRO

上市日期Oct 03, 2019

CEODr. Ram Aiyar, Ph.D.

Korro Bio Inc公司高管



名称

名称/职务

职务

持股

持股变动

Dr. Nessan Bermingham, Ph.D.

Independent Chairman of the Board

35.11K

Mr. Jeffrey (Jeff) Cerio, Pharm.D.

Senior Vice President, General Counsel, Corporate Secretary

Mr. Oliver Dolan

Principal Accounting Officer

Dr. Ali Behbahani, M.D.

Independent Director

Mr. Venkat Krishnamurthy, Ph.D.

Senior Vice President - Platform

Ms. Stephanie Engels

Senior Vice President - People and Culture

Dr. Rachel Meyers, Ph.D.

Independent Director

Dr. Katharine (Kate) Knobil, M.D.

Independent Director

Mr. Todd Chappell

Chief Operating Officer

Dr. Ram Aiyar, Ph.D.

President, Chief Executive Office (Principal Executive Officer), Interim Chief Financial Officer and Principal Financial Officer, Director

名称

名称/职务

职务

持股

持股变动

Dr. Nessan Bermingham, Ph.D.

Independent Chairman of the Board

35.11K

Mr. Jeffrey (Jeff) Cerio, Pharm.D.

Senior Vice President, General Counsel, Corporate Secretary

Mr. Oliver Dolan

Principal Accounting Officer

Dr. Ali Behbahani, M.D.

Independent Director

Mr. Venkat Krishnamurthy, Ph.D.

Senior Vice President - Platform

Ms. Stephanie Engels

Senior Vice President - People and Culture

收入明细

FY2025Q2

FY2025Q1

FY2024

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

1.46M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 12月5日周五

持股股东

股东类型

持股股东

占比

Atlas Venture

12.08%

New Enterprise Associates (NEA)

11.58%

Driehaus Capital Management, LLC

7.14%

Fidelity Management & Research Company LLC

5.99%

Platanus Investment LLC

5.74%

其他

57.48%

持股股东

占比

Atlas Venture

12.08%

New Enterprise Associates (NEA)

11.58%

Driehaus Capital Management, LLC

7.14%

Fidelity Management & Research Company LLC

5.99%

Platanus Investment LLC

5.74%

其他

57.48%

股东类型

持股股东

占比

Investment Advisor

37.54%

Venture Capital

24.12%

Hedge Fund

23.55%

Investment Advisor/Hedge Fund

16.05%

Corporation

5.74%

Research Firm

2.19%

Individual Investor

1.54%

Private Equity

0.34%

Bank and Trust

0.27%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

186

9.33M

99.33%

-1.07M

2025Q2

186

10.38M

110.55%

-200.85K

2025Q1

189

10.53M

112.24%

-76.97K

2024Q4

194

10.26M

109.50%

+485.90K

2024Q3

177

9.16M

98.29%

-245.98K

2024Q2

167

9.06M

97.57%

+507.87K

2024Q1

179

7.52M

93.89%

+737.20K

2023Q4

198

7.18M

91.01%

+1.51M

2023Q3

223

264.10K

35.84%

-47.15K

2023Q2

235

150.53K

21.10%

-156.09K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Atlas Venture

1.14M

12.11%

Jun 30, 2025

New Enterprise Associates (NEA)

1.09M

11.62%

Jun 30, 2025

Driehaus Capital Management, LLC

580.86K

6.19%

-1.59K

-0.27%

Jun 30, 2025

Fidelity Management & Research Company LLC

639.22K

6.81%

-4.05K

-0.63%

Jun 30, 2025

Platanus Investment LLC

540.16K

5.75%

Apr 15, 2025

Point72 Asset Management, L.P.

540.07K

5.75%

+19.18K

+3.68%

Jun 30, 2025

Cormorant Asset Management, LP

465.00K

4.95%

+84.70K

+22.27%

Jun 30, 2025

Invus Public Equities Advisors, LLC

418.83K

4.46%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

423.16K

4.51%

+15.35K

+3.76%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.05%

Avantis US Small Cap Equity ETF

0.02%

Global X Russell 2000 ETF

0.01%

Proshares Ultra Russell 2000

0.01%

ProShares UltraPro Russell2000

SPDR Portfolio MSCI Global Stock Market ETF

ProShares Hedge Replication ETF

Invesco Dorsey Wright SmallCap Momentum ETF

iShares Russell 2000 Growth ETF

iShares Russell 3000 ETF

iShares Micro-Cap ETF

占比0.05%

Avantis US Small Cap Equity ETF

占比0.02%

Global X Russell 2000 ETF

占比0.01%

Proshares Ultra Russell 2000

占比0.01%

ProShares UltraPro Russell2000

占比0%

SPDR Portfolio MSCI Global Stock Market ETF

占比0%

ProShares Hedge Replication ETF

占比0%

Invesco Dorsey Wright SmallCap Momentum ETF

占比0%

iShares Russell 2000 Growth ETF

占比0%

iShares Russell 3000 ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

公告日期

类型

比率

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

Nov 03, 2023

Merger

50→1

常见问题

Korro Bio Inc的前五大股东是谁？



Korro Bio Inc 的前五大股东如下：
Atlas Venture持有股份：1.14M，占总股份比例：12.11%。
New Enterprise Associates (NEA)持有股份：1.09M，占总股份比例：11.62%。
Driehaus Capital Management, LLC持有股份：580.86K，占总股份比例：6.19%。
Fidelity Management & Research Company LLC持有股份：639.22K，占总股份比例：6.81%。
Platanus Investment LLC持有股份：540.16K，占总股份比例：5.75%。